Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating restated by stock analysts at BMO Capital Markets in a research report issued on Friday, September 22nd. They presently have a $160.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $221.00. BMO Capital Markets’ price objective indicates a potential upside of 175.67% from the stock’s current price.
A number of other equities research analysts have also commented on ICPT. Wedbush reissued an “outperform” rating and issued a $231.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, May 26th. ValuEngine raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Credit Suisse Group set a $201.00 price target on Intercept Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 3rd. Cowen and Company reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, June 12th. Finally, BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $162.88.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 0.71% during trading on Friday, hitting $58.04. 2,740,297 shares of the company traded hands. The stock has a 50-day moving average price of $106.75 and a 200-day moving average price of $115.74. Intercept Pharmaceuticals has a 12-month low of $57.31 and a 12-month high of $172.75. The firm’s market capitalization is $1.46 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating analysts’ consensus estimates of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. Intercept Pharmaceuticals’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.14) EPS. Equities analysts expect that Intercept Pharmaceuticals will post ($13.99) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Rating Reiterated by BMO Capital Markets” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/09/30/intercept-pharmaceuticals-inc-icpt-price-target-lowered-to-160-00-at-bmo-capital-markets.html.
In other Intercept Pharmaceuticals news, insider Lisa Bright sold 253 shares of the firm’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $111.31, for a total value of $28,161.43. Following the completion of the transaction, the insider now owns 23,324 shares in the company, valued at approximately $2,596,194.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO David Shapiro sold 1,250 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the transaction, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,013 shares of company stock valued at $966,747. 9.20% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. WFG Advisors LP raised its holdings in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 132 shares in the last quarter. US Bancorp DE purchased a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at about $130,000. IFP Advisors Inc raised its holdings in shares of Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 730 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at about $170,000. Institutional investors and hedge funds own 82.19% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.